US15117F8077 - Common Stock
CELLECTAR BIOSCIENCES INC
NASDAQ:CLRB (5/2/2024, 3:55:38 PM)
After market: 3.32 -0.02 (-0.6%)3.34
+0.18 (+5.7%)
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on to develop PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.
CELLECTAR BIOSCIENCES INC
100 Campus Drive
Florham Park NEW JERSEY 07932
P: 16084418120
CEO: JamesV.Caruso
Employees: 15
Website: https://www.cellectar.com/
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains.
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private.
CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Management to host a conference call today at 8:30 am ET
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
Here you can normally see the latest stock twits on CLRB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: